AstraZeneca and Amgen said Tezspire (tezepelumab) cleared coprimary endpoints and all key secondary endpoints in a phase 3 trial for eosinophilic esophagitis (EoE). The Crossing study result positions Tezspire for potential approval as a third indication, adding to its asthma and chronic rhinosinusitis with nasal polyps footprint. The development could widen Tezspire’s commercial reach in an immunology market where approved biologic options exist, and it brings the timeline for regulatory submissions into focus given the strength of the phase 3 readout.